Lysine (lys) (acetylated) antibody

Details for Product No. ABIN1105211
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Epitope
acetylated
(15), (8), (5), (4), (4), (1), (1), (1)
Reactivity
Chemical
(27), (6), (4), (3), (3), (3), (2)
Host
Mouse
(28), (2), (1)
Clonality (Clone)
Monoclonal ()
Conjugate
Un-conjugated
(7), (7), (3), (1), (1)
Application
Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA), Western Blotting (WB)
(28), (16), (14), (13), (9), (5), (2), (1), (1), (1)
Pubmed 4 references available
Quantity 25 μg
Shipping to United States (Change)
Availability Will be delivered in 6 to 8 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN1105211
253.00 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Clone 7F8
Isotype IgG1
Purification Affinity Chromatography on Protein G
Alternative Name Lysine
Target Type Chemical
Background Post-translational modifications of proteins play critical roles in the regulation and function of many known biological processes. Proteins can be post-translationally modified in many different ways, and a common posttranscriptional modification of Lysine involves acetylation (1). The conserved amino-terminal domains of the four core histones (H2A, H2B, H3 and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (2). Protein posttranslational reversible lysine Nε-acetylation and deacetylation have been recognized as an emerging intracellular signaling mechanism that plays critical roles in regulating gene transcription, cell-cycle progression, apoptosis, DNA repair, and cytoskeletal organization (3). The regulation of protein acetylation status is impaired in the pathologies of cancer and polyglutamine diseases (4), and HDACs have become promising targets for anticancer drugs currently in development (5).Synonyms: AcK, acetyl Lysine, acetyl-Lysine
Research Area Metabolism
Application Notes Optimal working dilution should be determined by the investigator.
Restrictions For Research Use only
Concentration 1.0 mg/mL
Buffer PBS, pH 7.4 containing 0.09 % Sodium Azide in 50 % Glycerol
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Background publications Hassig, Schreiber: "Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs." in: Current opinion in chemical biology, Vol. 1, Issue 3, pp. 300-8, 1998 (PubMed).

Vigushin, Coombes: "Targeted histone deacetylase inhibition for cancer therapy." in: Current cancer drug targets, Vol. 4, Issue 2, pp. 205-18, 2004 (PubMed).

Yang: "Lysine acetylation and the bromodomain: a new partnership for signaling." in: BioEssays : news and reviews in molecular, cellular and developmental biology, Vol. 26, Issue 10, pp. 1076-87, 2004 (PubMed).

Yang: "Multisite protein modification and intramolecular signaling." in: Oncogene, Vol. 24, Issue 10, pp. 1653-62, 2005 (PubMed).

Validation Images
Did you look for something else?
back to top